المؤلفون: Deppas JJ; Cancer Therapeutics Program, UPMC Hillman Cancer Center, University of Pittsburgh, Room G27e 5117 Centre Ave, Pittsburgh, PA, 15213, USA.; Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA, USA., Kiesel BF; Cancer Therapeutics Program, UPMC Hillman Cancer Center, University of Pittsburgh, Room G27e 5117 Centre Ave, Pittsburgh, PA, 15213, USA.; Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA, USA., Guo J; Cancer Therapeutics Program, UPMC Hillman Cancer Center, University of Pittsburgh, Room G27e 5117 Centre Ave, Pittsburgh, PA, 15213, USA., Parise RA; Cancer Therapeutics Program, UPMC Hillman Cancer Center, University of Pittsburgh, Room G27e 5117 Centre Ave, Pittsburgh, PA, 15213, USA., Clump DA; Department of Radiation Oncology, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA., D'Argenio DZ; Department of Biomedical Engineering, University of Southern California, Los Angeles, CA, USA., Bakkenist CJ; Department of Radiation Oncology, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.; Department of Pharmacology and Chemical Biology, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA., Beumer JH; Cancer Therapeutics Program, UPMC Hillman Cancer Center, University of Pittsburgh, Room G27e 5117 Centre Ave, Pittsburgh, PA, 15213, USA. beumerj@gmail.com.; Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA, USA. beumerj@gmail.com.; Division of Hematology/Oncology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA. beumerj@gmail.com.

المصدر: Cancer chemotherapy and pharmacology [Cancer Chemother Pharmacol] 2024 Aug; Vol. 94 (2), pp. 271-283. Date of Electronic Publication: 2024 May 14.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Springer Verlag Country of Publication: Germany NLM ID: 7806519 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-0843 (Electronic) Linking ISSN: 03445704 NLM ISO Abbreviation: Cancer Chemother Pharmacol Subsets: MEDLINE

مواضيع طبية MeSH: Ataxia Telangiectasia Mutated Proteins*/antagonists & inhibitors , Mice, Inbred BALB C* , Dose-Response Relationship, Drug*, Animals ; Female ; Mice ; Tissue Distribution ; Pyrazines/pharmacokinetics ; Pyrazines/administration & dosage ; Tandem Mass Spectrometry ; Humans ; Pyrazoles/pharmacokinetics ; Pyrazoles/administration & dosage ; Nonlinear Dynamics ; Administration, Intravenous ; Isoxazoles

المؤلفون: Malhotra MK; Division of Hematology/Oncology, Department of Medicine, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA., Pahuja S; Division of Hematology/Oncology, Department of Medicine, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA., Kiesel BF; Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, PA, USA.; Department of Pharmaceutical Sciences, School of Pharmacy, Pittsburgh, PA, USA., Appleman LJ; Division of Hematology/Oncology, Department of Medicine, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.; Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, PA, USA., Ding F; Biostatistics Facility, UPMC Hillman Cancer Center, Pittsburgh, PA, USA., Lin Y; Department of Biostatistics, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA, USA.; UPMC Hillman Cancer Center, Pittsburgh, PA, USA., Tawbi HA; Division of Hematology/Oncology, Department of Medicine, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.; Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, PA, USA., Stoller RG; Division of Hematology/Oncology, Department of Medicine, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.; Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, PA, USA., Lee JJ; Division of Hematology/Oncology, Department of Medicine, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.; Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, PA, USA., Belani CP; Penn State Cancer Institute, Penn State College of Medicine, Hershey, PA, USA., Chen AP; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, USA.; Center for Cancer Research, National Cancer Institute, Bethesda, USA., Giranda VL; AbbVie Laboratories, North Chicago, IL, USA., Shepherd SP; AbbVie Laboratories, North Chicago, IL, USA., Emens LA; Division of Hematology/Oncology, Department of Medicine, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.; Cancer Immunology and Immunotherapy Program, UPMC Hillman Cancer Center, Pittsburgh, PA, USA., Ivy SP; Investigational Drug Branch, Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, USA., Chu E; Division of Hematology/Oncology, Department of Medicine, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.; Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, PA, USA.; Cancer Therapeutics Program, Montefiore Einstein Cancer Center, Bronx, NY, USA., Beumer JH; Division of Hematology/Oncology, Department of Medicine, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA. beumerj@gmail.com.; Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, PA, USA. beumerj@gmail.com.; Department of Pharmaceutical Sciences, School of Pharmacy, Pittsburgh, PA, USA. beumerj@gmail.com.; UPMC Hillman Cancer Center, Hillman Research Pavilion, Room G27E, 5117 Centre Avenue, Pittsburgh, PA, 15213-1863, USA. beumerj@gmail.com., Puhalla S; Division of Hematology/Oncology, Department of Medicine, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA. puhallasl@upmc.edu.; Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, PA, USA. puhallasl@upmc.edu.; UPMC Magee Women's Hospital, 300 Halket Street, Pittsburgh, PA, 15213, USA. puhallasl@upmc.edu.

المصدر: Breast cancer research and treatment [Breast Cancer Res Treat] 2023 Apr; Vol. 198 (3), pp. 487-498. Date of Electronic Publication: 2023 Feb 28.

نوع المنشور: Clinical Trial, Phase I; Journal Article

بيانات الدورية: Publisher: Kluwer Academic Country of Publication: Netherlands NLM ID: 8111104 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-7217 (Electronic) Linking ISSN: 01676806 NLM ISO Abbreviation: Breast Cancer Res Treat Subsets: MEDLINE

مواضيع طبية MeSH: Breast Neoplasms*/pathology , Triple Negative Breast Neoplasms*/drug therapy , Triple Negative Breast Neoplasms*/etiology , Anemia*/chemically induced, Humans ; Female ; Carboplatin ; Paclitaxel ; Antineoplastic Combined Chemotherapy Protocols/adverse effects

المؤلفون: Kiesel BF; Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.; Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, Pennsylvania, USA., Parise RA; Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA., Krishnamurthy A; Division of Hematology-Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA., Gore S; Investigational Drug Branch, Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland, USA., Beumer JH; Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.; Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.; Division of Hematology-Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.

المصدر: Biomedical chromatography : BMC [Biomed Chromatogr] 2022 Nov; Vol. 36 (11), pp. e5455. Date of Electronic Publication: 2022 Aug 08.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Wiley Country of Publication: England NLM ID: 8610241 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1099-0801 (Electronic) Linking ISSN: 02693879 NLM ISO Abbreviation: Biomed Chromatogr Subsets: MEDLINE

مواضيع طبية MeSH: Ataxia Telangiectasia* , Tandem Mass Spectrometry*/methods, Acetonitriles ; Chromatography, Liquid/methods ; DNA ; Humans ; Protein Kinase Inhibitors ; Reproducibility of Results ; Water

المؤلفون: Kiesel BF; Cancer Therapeutics Program, UPMC Hillman Cancer Center, Room G27e, 5117 Centre Ave, Pittsburgh, PA, 15213, USA.; Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA, USA., Deppas JJ; Cancer Therapeutics Program, UPMC Hillman Cancer Center, Room G27e, 5117 Centre Ave, Pittsburgh, PA, 15213, USA.; Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA, USA., Guo J; Cancer Therapeutics Program, UPMC Hillman Cancer Center, Room G27e, 5117 Centre Ave, Pittsburgh, PA, 15213, USA., Parise RA; Cancer Therapeutics Program, UPMC Hillman Cancer Center, Room G27e, 5117 Centre Ave, Pittsburgh, PA, 15213, USA., Clump DA; Department of Radiation Oncology, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA., Bakkenist CJ; Department of Radiation Oncology, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.; Department of Pharmacology and Chemical Biology, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA., Beumer JH; Cancer Therapeutics Program, UPMC Hillman Cancer Center, Room G27e, 5117 Centre Ave, Pittsburgh, PA, 15213, USA. beumerj@gmail.com.; Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA, USA. beumerj@gmail.com.; Division of Hematology-Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA. beumerj@gmail.com.

المصدر: Cancer chemotherapy and pharmacology [Cancer Chemother Pharmacol] 2022 Jun; Vol. 89 (6), pp. 795-807. Date of Electronic Publication: 2022 May 04.

نوع المنشور: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Springer Verlag Country of Publication: Germany NLM ID: 7806519 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-0843 (Electronic) Linking ISSN: 03445704 NLM ISO Abbreviation: Cancer Chemother Pharmacol Subsets: MEDLINE

مواضيع طبية MeSH: Protein Kinase Inhibitors*/pharmacokinetics , Tandem Mass Spectrometry*, Animals ; Ataxia Telangiectasia Mutated Proteins ; Biological Availability ; Chromatography, Liquid ; Humans ; Mice ; Tissue Distribution

المؤلفون: Manzo J; Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, PA, USA., Puhalla S; Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, PA, USA.; Division of Hematology/Oncology, Department of Medicine, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA., Pahuja S; Division of Hematology/Oncology, Department of Medicine, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA., Ding F; Biostatistics Facility, UPMC Hillman Cancer Center, Pittsburgh, PA, USA., Lin Y; Biostatistics Facility, UPMC Hillman Cancer Center, Pittsburgh, PA, USA.; Department of Biostatistics, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA, USA., Appleman L; Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, PA, USA.; Division of Hematology/Oncology, Department of Medicine, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA., Tawbi H; Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, PA, USA.; Division of Hematology/Oncology, Department of Medicine, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA., Stoller R; Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, PA, USA.; Division of Hematology/Oncology, Department of Medicine, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA., Lee JJ; Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, PA, USA.; Division of Hematology/Oncology, Department of Medicine, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA., Diergaarde B; Department of Biostatistics, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA, USA., Kiesel BF; Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, PA, USA.; Department of Pharmaceutical Sciences, School of Pharmacy, Pittsburgh, PA, USA., Yu J; Department of Pathology, Magee-Womens Hospital of University of Pittsburgh Medical Center, Pittsburgh, USA., Tan AR; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.; Levine Cancer Institute, Charlotte, NC, USA., Belani CP; Penn State Cancer Institute, Penn State College of Medicine, Hershey, PA, USA., Chew H; Division of Hematology/Oncology, Department of Medicine, University of California Davis, Sacramento, CA, USA., Garcia AA; Department of Medicine, Louisiana State University, New Orleans, LA, USA., Morgan RJ; Department of Molecular Pharmacology, City of Hope Beckman Research Institute, Duarte, CA, USA., Wahner Hendrickson AE; Department of Oncology, Mayo Clinic, Rochester, MN, USA., Visscher DW; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA., Hurley RM; Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN, USA., Kaufmann SH; Department of Oncology, Mayo Clinic, Rochester, MN, USA.; Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN, USA., Swisher EM; Department of Obstetrics and Gynecologic, University of Washington, Seattle, WA, USA., Oesterreich S; Department of Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA., Katz T; Department of Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA., Ji J; Clinical Pharmacodynamic Biomarkers Program, Applied/Developmental Research Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD, USA., Zhang Y; Clinical Pharmacodynamic Biomarkers Program, Applied/Developmental Research Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD, USA., Parchment RE; Investigational Drug Branch, Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, USA., Chen A; Investigational Drug Branch, Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, USA., Duan W; Department of Human and Molecular Genetics, The Florida International University, Miami, FL, USA., Giranda V; AbbVie Laboratories, North Chicago, IL, USA., Shepherd SP; AbbVie Laboratories, North Chicago, IL, USA., Ivy SP; Investigational Drug Branch, Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, USA., Chu E; Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, PA, USA.; Division of Hematology/Oncology, Department of Medicine, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA., Beumer JH; Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, PA, USA. beumerj@gmail.com.; Division of Hematology/Oncology, Department of Medicine, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA. beumerj@gmail.com.; Department of Pharmaceutical Sciences, School of Pharmacy, Pittsburgh, PA, USA. beumerj@gmail.com.

مؤلفون مشاركون: ETCTN-8282 study team

المصدر: Cancer chemotherapy and pharmacology [Cancer Chemother Pharmacol] 2022 May; Vol. 89 (5), pp. 721-735. Date of Electronic Publication: 2022 Apr 18.

نوع المنشور: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural

بيانات الدورية: Publisher: Springer Verlag Country of Publication: Germany NLM ID: 7806519 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-0843 (Electronic) Linking ISSN: 03445704 NLM ISO Abbreviation: Cancer Chemother Pharmacol Subsets: MEDLINE

مواضيع طبية MeSH: Lymphopenia*/chemically induced , Lymphopenia*/drug therapy , Ovarian Neoplasms*/drug therapy , Ovarian Neoplasms*/genetics , Triple Negative Breast Neoplasms*/drug therapy, Antineoplastic Combined Chemotherapy Protocols ; BRCA1 Protein/genetics ; BRCA2 Protein/genetics ; Benzimidazoles ; Female ; Humans ; Nausea/chemically induced ; Platinum/therapeutic use ; Poly(ADP-ribose) Polymerase Inhibitors/adverse effects ; Seizures/chemically induced

المؤلفون: Kiesel BF; Cancer Therapeutics Drug Discovery Program, University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA.; Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA, USA., Guo J; Cancer Therapeutics Drug Discovery Program, University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA., Parise RA; Cancer Therapeutics Drug Discovery Program, University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA., Venkataramanan R; Cancer Therapeutics Drug Discovery Program, University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA.; Department of Pathology, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA., Clump DA; Department of Radiation Oncology, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA., Bakkenist CJ; Department of Radiation Oncology, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.; Department of Pharmacology and Chemical Biology, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA., Beumer JH; Cancer Therapeutics Drug Discovery Program, University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA. beumerj@gmail.com.; Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA, USA. beumerj@gmail.com.; Division of Hematology-Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA. beumerj@gmail.com.; UPMC Hillman Cancer Center, Room G27e, 5117 Centre Ave, Pittsburgh, PA, 15213, USA. beumerj@gmail.com.

المصدر: Cancer chemotherapy and pharmacology [Cancer Chemother Pharmacol] 2022 Feb; Vol. 89 (2), pp. 231-242. Date of Electronic Publication: 2022 Jan 23.

نوع المنشور: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Springer Verlag Country of Publication: Germany NLM ID: 7806519 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-0843 (Electronic) Linking ISSN: 03445704 NLM ISO Abbreviation: Cancer Chemother Pharmacol Subsets: MEDLINE

مواضيع طبية MeSH: Models, Biological*, Indoles/*pharmacokinetics , Morpholines/*pharmacokinetics , Protein Kinase Inhibitors/*pharmacokinetics , Pyrimidines/*pharmacokinetics , Sulfonamides/*pharmacokinetics, Animals ; Ataxia Telangiectasia Mutated Proteins/antagonists & inhibitors ; Biological Availability ; Chromatography, Liquid ; Dose-Response Relationship, Drug ; Female ; Indoles/administration & dosage ; Mice ; Mice, Inbred BALB C ; Morpholines/administration & dosage ; Protein Kinase Inhibitors/administration & dosage ; Pyrimidines/administration & dosage ; Sulfonamides/administration & dosage ; Tandem Mass Spectrometry ; Tissue Distribution

المؤلفون: Tan AR; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA. Antoinette.Tan@atriumhealth.org.; Atrium Health, Levine Cancer Institute, 1021 Morehead Medical Drive, Charlotte, NC, 28204, USA. Antoinette.Tan@atriumhealth.org., Chan N; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA., Kiesel BF; University of Pittsburgh, Pittsburgh, PA, USA., Stein MN; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.; Columbia University Medical Center, New York, NY, USA., Moss RA; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.; Bristol-Myers Squibb, Lawrenceville, NJ, USA., Malhotra J; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA., Aisner J; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA., Shah M; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA., Gounder M; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA., Lin H; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA., Kane MP; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA., Lin Y; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA., Ji J; Frederick National Lab for Cancer Research, Bethesda, MD, USA., Chen A; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, USA., Beumer JH; University of Pittsburgh, Pittsburgh, PA, USA., Mehnert JM; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.; New York University Langone Health's Perlmutter Cancer Center, New York, NY, USA.

المصدر: Cancer chemotherapy and pharmacology [Cancer Chemother Pharmacol] 2022 Jan; Vol. 89 (1), pp. 49-58. Date of Electronic Publication: 2021 Oct 20.

نوع المنشور: Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural

بيانات الدورية: Publisher: Springer Verlag Country of Publication: Germany NLM ID: 7806519 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-0843 (Electronic) Linking ISSN: 03445704 NLM ISO Abbreviation: Cancer Chemother Pharmacol Subsets: MEDLINE

مواضيع طبية MeSH: Antineoplastic Combined Chemotherapy Protocols/*therapeutic use , Benzimidazoles/*pharmacokinetics , Cyclophosphamide/*pharmacokinetics , Neoplasms/*drug therapy, Adult ; Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Benzimidazoles/administration & dosage ; Breast Neoplasms/drug therapy ; Breast Neoplasms/pathology ; Cyclophosphamide/administration & dosage ; Cyclophosphamide/blood ; Doxorubicin/administration & dosage ; Female ; Humans ; Male ; Maximum Tolerated Dose ; Middle Aged ; Neoplasms/pathology ; Poly Adenosine Diphosphate Ribose/blood ; Poly(ADP-ribose) Polymerase Inhibitors/administration & dosage ; Poly(ADP-ribose) Polymerase Inhibitors/pharmacokinetics ; Poly(ADP-ribose) Polymerase Inhibitors/therapeutic use

المؤلفون: Jacobs SA; NSABP Foundation, Inc., Pittsburgh, Pennsylvania. Samuel.jacobs@nsabp.org ashok.srinivasan@nsabp.org., Lee JJ; NSABP Foundation, Inc., Pittsburgh, Pennsylvania.; UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania.; UPMC, Pittsburgh, Pennsylvania., George TJ; NSABP Foundation, Inc., Pittsburgh, Pennsylvania.; University of Florida, Gainesville, Florida., Wade JL 3rd; NSABP Foundation, Inc., Pittsburgh, Pennsylvania.; Cancer Care Specialists of Illinois, Decatur, Illinois., Stella PJ; NSABP Foundation, Inc., Pittsburgh, Pennsylvania.; St. Joseph Mercy Health System, Ann Arbor, Michigan., Wang D; NSABP Foundation, Inc., Pittsburgh, Pennsylvania.; Henry Ford Cancer Institute, Detroit, Michigan., Sama AR; NSABP Foundation, Inc., Pittsburgh, Pennsylvania.; Sidney Kimmel Medical College, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania., Piette F; International Drug Development Institute (IDDI), Louvain la Neuve, Belgium., Pogue-Geile KL; NSABP Foundation, Inc., Pittsburgh, Pennsylvania., Kim RS; NSABP Foundation, Inc., Pittsburgh, Pennsylvania., Gavin PG; NSABP Foundation, Inc., Pittsburgh, Pennsylvania., Lipchik C; NSABP Foundation, Inc., Pittsburgh, Pennsylvania., Feng H; NSABP Foundation, Inc., Pittsburgh, Pennsylvania., Wang Y; NSABP Foundation, Inc., Pittsburgh, Pennsylvania., Finnigan M; NSABP Foundation, Inc., Pittsburgh, Pennsylvania., Kiesel BF; UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania.; UPMC, Pittsburgh, Pennsylvania., Beumer JH; UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania.; UPMC, Pittsburgh, Pennsylvania., Wolmark N; NSABP Foundation, Inc., Pittsburgh, Pennsylvania.; UPMC, Pittsburgh, Pennsylvania., Lucas PC; NSABP Foundation, Inc., Pittsburgh, Pennsylvania.; Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania., Allegra CJ; NSABP Foundation, Inc., Pittsburgh, Pennsylvania.; University of Florida, Gainesville, Florida., Srinivasan A; NSABP Foundation, Inc., Pittsburgh, Pennsylvania. Samuel.jacobs@nsabp.org ashok.srinivasan@nsabp.org.

المصدر: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2021 Mar 15; Vol. 27 (6), pp. 1612-1622. Date of Electronic Publication: 2020 Nov 17.

نوع المنشور: Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: The Association Country of Publication: United States NLM ID: 9502500 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE

مواضيع طبية MeSH: Drug Resistance, Neoplasm* , Mutation*, Antineoplastic Combined Chemotherapy Protocols/*therapeutic use , Biomarkers, Tumor/*genetics , Colorectal Neoplasms/*drug therapy, Adult ; Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols/pharmacokinetics ; Cetuximab/administration & dosage ; Class I Phosphatidylinositol 3-Kinases/genetics ; Colorectal Neoplasms/genetics ; Colorectal Neoplasms/metabolism ; Colorectal Neoplasms/pathology ; Female ; Follow-Up Studies ; GTP Phosphohydrolases/genetics ; Humans ; Male ; Maximum Tolerated Dose ; Membrane Proteins/genetics ; Middle Aged ; Neoplasm Metastasis ; Panitumumab/administration & dosage ; Prognosis ; Proto-Oncogene Proteins B-raf/genetics ; Proto-Oncogene Proteins p21(ras)/genetics ; Quinolines/administration & dosage ; Retrospective Studies ; Tissue Distribution

المؤلفون: Joshi A; Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA, 15261, USA., Kiesel BF; Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA, 15261, USA.; Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, PA, USA., Chaphekar N; Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA, 15261, USA., Jones R; Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, PA, USA., Guo J; Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, PA, USA., Kunos CA; Investigational Drug Branch, Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, USA., Taylor S; Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA, 15261, USA.; Division of Gynecologic Oncology, Department of Obstetrics, Gynecology, and Reproductive Medicine, University of Pittsburgh-Magee Women's Hospital, Pittsburgh, PA, USA., Chu E; Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, PA, USA.; Division of Hematology-Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA., Venkataramanan R; Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA, 15261, USA. rv@pitt.edu.; Department of Pathology, University of Pittsburgh, Pittsburgh, PA, 15261, USA. rv@pitt.edu., Beumer JH; Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA, 15261, USA. beumerj@gmail.com.; Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, PA, USA. beumerj@gmail.com.; Division of Hematology-Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA. beumerj@gmail.com.

المصدر: Cancer chemotherapy and pharmacology [Cancer Chemother Pharmacol] 2020 Nov; Vol. 86 (5), pp. 633-640. Date of Electronic Publication: 2020 Sep 28.

نوع المنشور: Journal Article; Research Support, N.I.H., Extramural

بيانات الدورية: Publisher: Springer Verlag Country of Publication: Germany NLM ID: 7806519 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-0843 (Electronic) Linking ISSN: 03445704 NLM ISO Abbreviation: Cancer Chemother Pharmacol Subsets: MEDLINE

مواضيع طبية MeSH: Cytochrome P-450 CYP1A2 Inhibitors/*pharmacokinetics , Cytochrome P-450 CYP2C19 Inducers/*pharmacokinetics , Neoplasms/*therapy , Pyridines/*pharmacokinetics , Radiation-Sensitizing Agents/*pharmacokinetics , Thiosemicarbazones/*pharmacokinetics, Cells, Cultured ; Chemoradiotherapy/methods ; Chromatography, High Pressure Liquid ; Cytochrome P-450 CYP1A2/metabolism ; Cytochrome P-450 CYP1A2 Inhibitors/therapeutic use ; Cytochrome P-450 CYP2C19/metabolism ; Cytochrome P-450 CYP2C19 Inducers/therapeutic use ; Drug Evaluation, Preclinical ; Drug Interactions ; Emtricitabine/pharmacokinetics ; Hepatocytes ; Humans ; Inactivation, Metabolic ; Microsomes, Liver ; Primary Cell Culture ; Pyridines/therapeutic use ; Radiation-Sensitizing Agents/therapeutic use ; Tandem Mass Spectrometry ; Tenofovir/pharmacokinetics ; Thiosemicarbazones/therapeutic use

المؤلفون: Holleran JL; Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, PA, United States. Electronic address: HollJL@UPMC.EDU., Parise RA; Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, PA, United States. Electronic address: parisera@upmc.edu., Guo J; Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, PA, United States. Electronic address: guoxjx@UPMC.EDU., Kiesel BF; Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, PA, United States; Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA, United States. Electronic address: kieselb@upmc.edu., Taylor SE; Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, PA, United States; Division of Gynecologic Oncology, Department of Obstetrics, Gynecology, and Reproductive Medicine, University of Pittsburgh-Magee Women's Hospital, Pittsburgh, PA, United States. Electronic address: taylorse2@upmc.edu., Ivy SP; Investigational Drug Branch, Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, United States. Electronic address: ivyp@ctep.nci.nih.gov., Chu E; Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, PA, United States; Division of Hematology-Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, United States. Electronic address: chue2@upmc.edu., Beumer JH; Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, PA, United States; Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA, United States; Division of Hematology-Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, United States. Electronic address: beumerj@gmail.com.

المصدر: Journal of pharmaceutical and biomedical analysis [J Pharm Biomed Anal] 2020 Sep 10; Vol. 189, pp. 113464. Date of Electronic Publication: 2020 Jul 07.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Elsevier Science Country of Publication: England NLM ID: 8309336 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-264X (Electronic) Linking ISSN: 07317085 NLM ISO Abbreviation: J Pharm Biomed Anal Subsets: MEDLINE

مواضيع طبية MeSH: Iohexol*/analysis , Tandem Mass Spectrometry*, Chromatography, High Pressure Liquid ; Chromatography, Liquid ; Humans ; Reproducibility of Results